Given that HLA class I APM downregulation or loss is a known mechanism of immune evasion utilized by HNSCC (31), we explored the use of 5-aza to improve the tumor antigenicity of HNSCCs and improve clinical outcomes upon rechallenge with ICB therapy. The gene discussed is ANPEP; the disease is head and neck squamous cell carcinoma.